How are Polyplus Transfection addressing the challenges of delivery in RNAi therapies?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: How are Polyplus Transfection addressing the challenges of delivery in RNAi therapies?
Released on: December 18, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Polyplus Transfection started in 2001 to market transfection products developed in the lab of Dr Jean-Paul Behr

    Seminal work was published in 1989 on the use of polycationic lipids for the use of transfection  that led to several still popular transfection reagents

    Mark Bloomfield, CEO explains to PharmaVentures' Nigel Borshell how Polyplus Transfection fund their activities in therapeutics through the revenue producing side of the business with a focus on developing tools for delivering biomolecules into living cells.
  • Summary
  • Transcript
  • Participants
  • Company
Polyplus Transfection started in 2001 to market transfection products developed in the lab of Dr Jean-Paul Behr

Seminal work was published in 1989 on the use of polycationic lipids for the use of transfection  that led to several still popular transfection reagents

Mark Bloomfield, CEO explains to PharmaVentures' Nigel Borshell how Polyplus Transfection fund their activities in therapeutics through the revenue producing side of the business with a focus on developing tools for delivering biomolecules into living cells.
Polyplus Transfection started in 2001 to market transfection products developed in the lab of Dr. Jean-Paul Behr. Seminal work was published in 1989 on the use of polycationic lipids for the use of transfection  that led to several still popular transfection reagents. Mark Bloomfield, CEO explains to PharmaVentures' Nigel Borshell how Polyplus Transfection fund their activities in therapeutics through the revenue producing side of the business with a focus on developing tools for delivering biomolecules into living cells.
Mark Bloomfield
Polyplus Transfection
Polyplus Transfection/strong>